ConductScience.org, home

Paper328129

VM 26 and VP 16-213: a comparative analysis.

Rozencweig M and 3 others. Cancer, 1977. Cited by 161 papers, by iCite.

Cite this record

ConductScience Library. VM 26 and VP 16-213: a comparative analysis. Papers, record 328129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/328129

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
VM 26 and VP 16-213: a comparative analysis.
PubMed
Journal
Cancer
PubMed
Year
1977
PubMed
Publication types
Comparative Study, Journal Article, Review
PubMed
Citations, by iCite
161
iCite
Relative citation ratio, by iCite
8.32
iCite
Revised in PubMed
2019-06-19
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rozencweig MM
2Von Hoff DDD D
3Henney JEJ E
4Muggia FMF M

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PodophyllotoxinMajor topic
Animals
Brain Neoplasms
Drug Evaluation
Etoposide
Humans
Kinetics
Leukemia
Lung Neoplasms
Lymphoma
Neoplasms, Experimental
Teniposide
Urinary Bladder Neoplasms

Source PubMed

Download CSV of topics

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 161 citations.

PMIDTitleJournalYearIn PapersSource
15139794Pharmacokinetic optimisation of treatment with oral etoposide.Clin Pharmacokinet2004https://conductscience.org/library/papers/15139794PubMed
10789823Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.Drug Saf2000https://conductscience.org/library/papers/10789823PubMed
8699237Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.J Neurooncol1996https://conductscience.org/library/papers/8699237PubMed
8339387Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8339387PubMed
8070033Schedule-dependent topoisomerase II-inhibiting drugs.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8070033PubMed
8070021Teniposide: overview of its therapeutic potential in adult cancers.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8070021PubMed
7378272Effects of monocytopenia and anticoagulation in experimental Streptococcus sanguis endocarditis.Br J Exp Pathol1980https://conductscience.org/library/papers/7378272PubMed
7083457A phase I trial of continuous infusion VP16-213 (etoposide).Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083457PubMed
7083454Pharmacokinetics of VP16-213 given by different administration methods.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083454PubMed
7083453Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083453PubMed
7044595VM26: phase I and II studies.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044595PubMed
7044594VP16-213 (etoposide). A critical review of its activity.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044594PubMed
7044592The clinical pharmacology of VM26 and VP16-213. A brief overview.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044592PubMed
7031350[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].Klin Wochenschr1981https://conductscience.org/library/papers/7031350PubMed
6678864Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.Invest New Drugs1983https://conductscience.org/library/papers/6678864PubMed
6488441Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6488441PubMed
6282486VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6282486PubMed
4017164Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/4017164PubMed
3815721The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3815721PubMed
3581418In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3581418PubMed

See all 30 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/328129

GET https://conductscience.org/api/papers/v1/328129/cited_by?page=2